Jammu And Kashmir Headlines

Chronic Back Pain Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | J&J, Pfizer Inc, Vertebral Tech, Merck., Medtronic, Boston Scientific, Mesoblast Ltd.

 Breaking News
  • No posts were found

Chronic Back Pain Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | J&J, Pfizer Inc, Vertebral Tech, Merck., Medtronic, Boston Scientific, Mesoblast Ltd.

November 29
11:03 2023
Chronic Back Pain Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | J&J, Pfizer Inc, Vertebral Tech, Merck., Medtronic, Boston Scientific, Mesoblast Ltd.
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Back Pain pipeline constitutes key companies continuously working towards developing Chronic Back Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chronic Back Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Chronic Back Pain Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Back Pain Market.

 

Some of the key takeaways from the Chronic Back Pain Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Chronic Back Pain treatment therapies with a considerable amount of success over the years. 
  • Chronic Back Pain companies working in the treatment market are BDH Pharma, Synerkine Pharma, AnGes MG, Persica Pharmaceuticals, CHA Biotech, Eli Lilly and Company, Biogen, Mesoblast, Vertanical GmbH, and others, are developing therapies for the Chronic Back Pain treatment 
  • Emerging Chronic Back Pain therapies in the different phases of clinical trials are- BDH-001, SK-01, AMG0103, PP353, CordSTEM-DD, LY3857210, BIIB074, MPC-06-ID, VER-01, and others are expected to have a significant impact on the Chronic Back Pain market in the coming years.   
  • In May 2023, Scilex Holding Company announced complete enrollment in Phase 2, a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% triple-strength formulation for ZTlido, in subjects with acute Lower Back Pain.
  • In May 2023, Abbott announced that the United States Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
  • In February 2023, Camurus withdrew the application for CAM2038 to include chronic pain.
  • In February 2023, the FDA granted regenerative medicine advanced therapy (Rmat) designation to Rexlemestrocel–L for chronic lower back pain.

 

Chronic Back Pain Overview

A systemic or rheumatic disease can also induce back pain, even though the majority of cases are brought on by muscular strain, injuries, or spinal deformities. If pain lasts longer than three months, it is deemed chronic. Anywhere from the neck to the lower spine can experience back pain. The pain may originate in a central location and either be confined or dispersed throughout a large region.

 

Get a Free Sample PDF Report to know more about Chronic Back Pain Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-back-pain-pipeline-insight

 

Emerging Chronic Back Pain Drugs Under Different Phases of Clinical Development Include:

  • BDH-001: BDH Pharma
  • SK-01: Synerkine Pharma
  • AMG0103: AnGes MG
  • PP353: Persica Pharmaceuticals
  • CordSTEM-DD: CHA Biotech
  • LY3857210: Eli Lilly and Company
  • BIIB074: Biogen
  • MPC-06-ID: Mesoblast
  • VER-01: Vertanical GmbH

  

Chronic Back Pain Pipeline Therapeutics Assessment

  • Chronic Back Pain Assessment by Product Type
  • Chronic Back Pain By Stage and Product Type
  • Chronic Back Pain Assessment by Route of Administration
  • Chronic Back Pain By Stage and Route of Administration
  • Chronic Back Pain Assessment by Molecule Type
  • Chronic Back Pain by Stage and Molecule Type

 

DelveInsight’s Chronic Back Pain Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Chronic Back Pain product details are provided in the report. Download the Chronic Back Pain pipeline report to learn more about the emerging Chronic Back Pain therapies

 

Some of the key companies in the Chronic Back Pain Therapeutics Market include:

Key companies developing therapies for Chronic Back Pain are – Johnson & Johnson, Pfizer Inc, Vertebral Technologies, Inc., Merck & Co., Medtronic, Boston Scientific Corporation, Mesoblast Limited, SpineTheraStayble Therapeutics, Eli Lilly, Persica Pharmaceutials, and others.

 

Chronic Back Pain Pipeline Analysis:

The Chronic Back Pain pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Back Pain with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Back Pain Treatment.
  • Chronic Back Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Back Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Back Pain market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Back Pain drugs and therapies

 

Chronic Back Pain Pipeline Market Drivers

  • Rise in Anti-inflammatory Medications, increase in Nerve Cases are some of the important factors that are fueling the Chronic Back Pain Market.

 

Chronic Back Pain Pipeline Market Barriers

  • However, high Cost Associated with Drug Development, stringent Regulatory Policies and other factors are creating obstacles in the Chronic Back Pain Market growth.

 

Scope of Chronic Back Pain Pipeline Drug Insight    

  • Coverage: Global
  • Key Chronic Back Pain Companies: BDH Pharma, Synerkine Pharma, AnGes MG, Persica Pharmaceuticals, CHA Biotech, Eli Lilly and Company, Biogen, Mesoblast, Vertanical GmbH, and others
  • Key Chronic Back Pain Therapies: BDH-001, SK-01, AMG0103, PP353, CordSTEM-DD, LY3857210, BIIB074, MPC-06-ID, VER-01, and others
  • Chronic Back Pain Therapeutic Assessment: Chronic Back Pain current marketed and Chronic Back Pain emerging therapies
  • Chronic Back Pain Market Dynamics: Chronic Back Pain market drivers and Chronic Back Pain market barriers 

 

Request for Sample PDF Report for Chronic Back Pain Pipeline Assessment and clinical trials

 

Table of Contents

1. Chronic Back Pain Report Introduction

2. Chronic Back Pain Executive Summary

3. Chronic Back Pain Overview

4. Chronic Back Pain- Analytical Perspective In-depth Commercial Assessment

5. Chronic Back Pain Pipeline Therapeutics

6. Chronic Back Pain Late Stage Products (Phase II/III)

7. Chronic Back Pain Mid Stage Products (Phase II)

8. Chronic Back Pain Early Stage Products (Phase I)

9. Chronic Back Pain Preclinical Stage Products

10. Chronic Back Pain Therapeutics Assessment

11. Chronic Back Pain Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Back Pain Key Companies

14. Chronic Back Pain Key Products

15. Chronic Back Pain Unmet Needs

16 . Chronic Back Pain Market Drivers and Barriers

17. Chronic Back Pain Future Perspectives and Conclusion

18. Chronic Back Pain Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services